DDInter1833 DDInter899
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Tolvaptan {u} (Compound) resembles {v} (Compound) Conivaptan
Tolvaptan {u} (Compound) binds {v} (Gene) AVPR1A
Tolvaptan {u} (Compound) causes {v} (Side Effect) Renal impairment
Tolvaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Tolvaptan (Compound) resembles Conivaptan (Compound)
Tolvaptan (Compound) binds AVPR1A (Gene)
Tolvaptan (Compound) causes Renal impairment (Side Effect)
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Tolvaptan may lead to a major life threatening interaction when taken with Leflunomide
Tolvaptan may lead to a major life threatening interaction when taken with Lumacaftor